MMP9 and glioblastoma: Consistent with our findings, data from a phase 3 study of Bevacizumab in newly diagnosed glioblastoma showed that baseline plasma MMP9 predicts overall survival (OS) benefit from Bevacizumab, where patients with lower MMP9 (<quartile 1) derived a significant 5.2-month OS benefit from Bevacizumab42.